|
CN106046021A
|
|
Thienopyridine derivative containing bromine and preparation method and application of thienopyridine derivative
|
|
CN105770213A
|
|
Grape-seed specific mean-degree-of-polymerization procyanidin extract and preparing method and application thereof
|
|
CN105777775A
|
|
Crystal form IX of Tipidogrel free alkali and preparation method and application thereof
|
|
CN105566345A
|
|
(5-(2-cyanobenzyl)-4,5,6,7-tetrahydrothiophene[3,2-c]pyridine-2-yl)acetate crystal form III and preparation method and application thereof
|
|
CN105777774A
|
|
Crystal form X of Tipidogrel free alkali and preparation method and application thereof
|
|
CN105566346A
|
|
(5-(2-cyanobenzyl)-4,5,6,7-tetrahydrothiophene[3,2-c]pyridine-2-yl)acetate crystal form I and preparation method and application thereof
|
|
CN105372376A
|
|
Detection method of parecoxib sodium genotoxicity impurity and application thereof
|
|
CN105367629A
|
|
Hemopoietin mimic peptide, and preparation method and application thereof
|
|
CN105418754A
|
|
Hydroxyethyl starch modified hemopoietin mimic peptide and preparation thereof and application thereof
|
|
CN105418733A
|
|
Preparation and application of conjugate of cell penetrating polypeptide and antitumor drug
|
|
CN106032374A
|
|
Dabigatran etexilate of crystal variant form D, preparation method and uses thereof
|
|
CN106032375A
|
|
Dabigatran etexilate of crystal variant form F, preparation method and uses thereof
|
|
CN106032373A
|
|
Dabigatran etexilate of crystal variant form G, preparation method and uses thereof
|
|
CN106032376A
|
|
Dabigatran etexilate of crystal variant form C, preparation method and uses thereof
|
|
CN106032372A
|
|
Dabigatran etexilate of crystal variant form E, preparation method and uses thereof
|
|
CN106031708A
|
|
Pharmaceutical composition with effects of skin care, wrinkle removing, and anti-aging effect, and preparation method thereof
|
|
CN106032377A
|
|
Tetrazole type URAT1 inhibitors, preparing method, and uses of the inhibitors in treatment of hyperuricemia and gout
|
|
CN105820130A
|
|
Triazole propionate URAT1 inhibitor, preparation method thereof and purpose of triazole propionate URAT1 inhibitor for treating hyperuricemia and gout
|
|
CN105434328A
|
|
Roflumilast solid dispersion-containing solid preparation and preparation method thereof
|
|
CN105439974A
|
|
A preparing method of a lipase inhibitor
|
